Literature DB >> 29450880

A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema.

Starling Tolliver1, Jaqueline Graham1, Benjamin H Kaffenberger1.   

Abstract

Necrolytic migratory erythema (NME) is a rare skin disorder that is a cutaneous manifestation of the glucagonoma syndrome. It presents with annular eruptions of migrating erythematous papules and plaques with superficial epidermal necrosis, central flaccid bullae, and crusted erosions located primarily in the intertriginous areas. Treatment with the long-acting somatostatin analog Octreotide is a potential therapy to help ameliorate skin symptoms. We present a case of a patient with a 1-year history of a pancreatic glucagonoma that developed an ulcerated, plaque-like, weeping rash over multiple areas of their body despite current treatment with Octreotide and stable pancreatic tumor staging. The patient had a similar rash when initially diagnosed with a glucagonoma, and it quickly improved after Octreotide treatment. Clinical examination and biopsy were consistent with necrolytic migratory erythema due to an underlying glucagonoma. This rare case adds to our understanding of the clinical presentation of NME, as well as highlights the relapsing and remitting course, even if the underlying pancreatic tumor is stable and the patient is undergoing treatment.
© 2018 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29450880     DOI: 10.1111/ijd.13947

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  8 in total

1.  Glucagonoma syndrome with atypical necrolytic migratory erythema.

Authors:  Shujuan He; Weihui Zeng; Songmei Geng; Jinjing Jia
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Jan-Feb       Impact factor: 2.545

2.  Resolution of necrolytic migratory erythema with somatostatin analogue in a patient diagnosed with pancreatic glucagonoma.

Authors:  Cristina Saavedra; Angela Lamarca; Richard A Hubner
Journal:  BMJ Case Rep       Date:  2019-08-10

3.  Diarrhea: a missed D in the 4D glucagonoma syndrome.

Authors:  Marlone Cunha-Silva; Julia Guimarães da Costa; Guilherme Amorim Souza Faria; Juliana Yumi Massuda; Maria Letícia Cintra; Larissa Bastos Eloy da Costa; Vítor Marques Assad; Elaine Cristina de Ataíde; Daniel Ferraz de Campos Mazo; Tiago Sevá-Pereira
Journal:  Autops Case Rep       Date:  2019-11-27

4.  Application of Somatostatin, Chemotherapy Combined with TAE in Heterogeneous Glucagonoma Presented with Necrolytic Migratory Erythema.

Authors:  Chaoyong Shen; Jiaoxue He; Xiaoyan Le; Linmao Zheng; Dan Cao
Journal:  Onco Targets Ther       Date:  2019-12-20       Impact factor: 4.147

5.  Case of delayed diagnosis of necrolytic migratory erythema.

Authors:  Wissal Abdelli; Fatima Alaoui; Asmahen Souissi; Wiem Sassi; Ines Chelly; Slim Haouet; Mourad Mokni
Journal:  Clin Case Rep       Date:  2021-12-11

Review 6.  Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies.

Authors:  Yanping Li; Ruoqiu Fu; Tingting Jiang; Dongyu Duan; Yuanlin Wu; Chen Li; Ziwei Li; Rui Ni; Li Li; Yao Liu
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244

7.  How Many Times Can One Go Back to the Drawing Board before the Accurate Diagnosis and Surgical Treatment of Glucagonoma?

Authors:  Carmen Sorina Martin; Ovidiu Dumitru Parfeni; Liliana Gabriela Popa; Mara Madalina Mihai; Dana Terzea; Vlad Herlea; Mirela Gherghe; Razvan Adam; Osama Alnuaimi; Valentin Calu; Adrian Miron; Silvius Negoita; Cornelia Nitipir; Simona Fica
Journal:  Diagnostics (Basel)       Date:  2022-01-16

Review 8.  Third reported case of rare necrolytic migratory erythema associated with bacteraemia due to severe zinc deficiency after revisional Roux-En-Y gastric bypass: case report and literature review.

Authors:  Yassmin Salaheldin; Walid El Ansari; Esraa Aljaloudi; Wahiba Elhag
Journal:  Eat Weight Disord       Date:  2021-06-01       Impact factor: 4.652

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.